The Anticancer Efficacy of Platinum Azidothymidin on Hepatocellular Carcinoma Via Affecting the Telomerase and the BcL-2 Genes Expression.
The study of correlation between cancer biomarkers after treatment with anticancer drugs would represent a promising insight into the effectiveness of the drug. In this study, after induction of hepatocellular carcinoma, rats were divided into four groups: groups A and B as healthy or control group and negative untreated cancer group respectively; groups C and D were treated with platinum azido-thymidine (0.9 mg/kg/day), a novel anti-cancer drug, and azido-thymidine (AZT) (0.3 mg/kg/day) respectively. After induction of cancer, the telomerase and Bcl-2 expression were evaluated by real-time PCR (RT-qPCR), and also Bcl-2 concentration and telomerase activity were measured by enzyme-linked immunosorbent assay (ELISA) and telomerase repeat amplification protocol (TRAP) respectively. A significant correlation was observed between telomerase and Bcl-2 in untreated HCC-induced rats as compared to the control group. In untreated cancer group, a direct significant correlation between telomerase activity and expression (r = 0.453, p = 0.022*) and also a negative significant correlation between telomerase activity and Bcl-2 concentration (r = - 0.43, p = 0.034*) and also between telomerase and Bcl-2 expression (r = - 0.088, p = 0.006*) was observed. In drug-treated groups, there was a significant negative correlation between telomerase expression and Bcl-2 concentration (r = - 0.45, p = 0.025) only in the AZT-treated groups. Our results indicated a correlation between cancer factors in the untreated cancerous group B and in treated groups only limited to the azithoimidin-treated group (group D). Hence, it may be possible to use this strategy to develop remarkable anticancer drugs in future studies, though this hypothesis requires more in-depth research.